mTOR Pathway Inhibition, Anticancer Activity and In Silico Calculations of Novel Hydrazone Derivatives in Two- and Three-Dimensional Cultured Type 1 Endometrial Cancer Cells
The findings suggest that MVB1 and MVB2, especially MVB1, are promising candidates for further development as potential therapeutics for endometrial cancer by targeting the PI3K/AKT/mTOR pathway.
Authors
- Arif Mermer (ORCID: https://orcid.org/0000-0002-4789-7180)
- Turan Demircan (ORCID: https://orcid.org/0000-0002-2424-9893)
- Aslı Kireçtepe Aydın (ORCID: https://orcid.org/0000-0001-8289-5191)
- Muhammet Volkan Bülbül (ORCID: https://orcid.org/0000-0003-1526-2065)
- İlknur Keskin (ORCID: https://orcid.org/0000-0002-7059-1884)
- Fatih Kocabaş (ORCID: https://orcid.org/0000-0001-8096-6056)
- Bircan Kolbaşı (ORCID: https://orcid.org/0000-0001-7933-4262)
- Semiha Mervenur Kalender (ORCID: https://orcid.org/0000-0002-0885-3417)
Institutions
- Yeditepe University (TR)
- İstanbul Nişantaşı Üniversitesi (TR)
- Ağrı İbrahim Çeçen University (TR)
- Istanbul Medipol University (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Istanbul University (TR)
- Muğla University (TR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3390/ph17121562
- Citations
- 2
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- İstanbul Medipol Üniversitesi